HK1038313A1 - Methods of treating multiple myeloma and myeloma-induced bone resorption using antagonists of integrin / receptor binding - Google Patents

Methods of treating multiple myeloma and myeloma-induced bone resorption using antagonists of integrin / receptor binding

Info

Publication number
HK1038313A1
HK1038313A1 HK01109049.1A HK01109049A HK1038313A1 HK 1038313 A1 HK1038313 A1 HK 1038313A1 HK 01109049 A HK01109049 A HK 01109049A HK 1038313 A1 HK1038313 A1 HK 1038313A1
Authority
HK
Hong Kong
Prior art keywords
myeloma
antagonists
multiple myeloma
methods
integrin
Prior art date
Application number
HK01109049.1A
Other languages
English (en)
Inventor
Gregory R Mundy
Toshiyuki Yoneda
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of HK1038313A1 publication Critical patent/HK1038313A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2836—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Photoreceptors In Electrophotography (AREA)
HK01109049.1A 1998-09-14 2001-12-24 Methods of treating multiple myeloma and myeloma-induced bone resorption using antagonists of integrin / receptor binding HK1038313A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10018298P 1998-09-14 1998-09-14
PCT/US1999/021170 WO2000015247A2 (en) 1998-09-14 1999-09-13 Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists

Publications (1)

Publication Number Publication Date
HK1038313A1 true HK1038313A1 (en) 2002-03-15

Family

ID=22278506

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01109049.1A HK1038313A1 (en) 1998-09-14 2001-12-24 Methods of treating multiple myeloma and myeloma-induced bone resorption using antagonists of integrin / receptor binding

Country Status (29)

Country Link
US (1) US7211252B2 (ja)
EP (2) EP1113810B1 (ja)
JP (3) JP2002524529A (ja)
KR (1) KR100628818B1 (ja)
CN (1) CN1236815C (ja)
AT (1) ATE418999T1 (ja)
AU (1) AU757873B2 (ja)
BR (1) BR9913705A (ja)
CA (1) CA2343579C (ja)
CY (1) CY1109413T1 (ja)
CZ (1) CZ302997B6 (ja)
DE (1) DE69940206D1 (ja)
DK (1) DK1113810T3 (ja)
EA (1) EA004270B1 (ja)
EE (1) EE05558B1 (ja)
ES (1) ES2319831T3 (ja)
HK (1) HK1038313A1 (ja)
HU (1) HU229038B1 (ja)
IL (2) IL141877A0 (ja)
IS (1) IS2631B (ja)
NO (2) NO327855B1 (ja)
NZ (1) NZ511062A (ja)
PL (1) PL203114B1 (ja)
PT (1) PT1113810E (ja)
SI (1) SI1113810T1 (ja)
SK (1) SK287601B6 (ja)
TR (1) TR200100734T2 (ja)
WO (1) WO2000015247A2 (ja)
ZA (1) ZA200102032B (ja)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
ATE325623T1 (de) * 1999-09-14 2006-06-15 Biogen Idec Inc Therapien für chronische niereninsuffizienz unter verwendung von einem oder mehreren integrinantagonist(en)
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
AU2002356180A1 (en) * 2001-08-06 2003-03-10 The Regents Of The University Of California Methods for inhibiting angiogenesis
EP1718310A4 (en) * 2004-02-06 2009-05-06 Elan Pharm Inc METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
WO2007092471A2 (en) * 2006-02-03 2007-08-16 The Regents Of The University Of California Methods for inhibition of lymphangiogenesis and tumor metastasis
EP3042668B1 (en) * 2006-06-07 2018-09-19 The Board of Trustees of the Leland Stanford Junior University Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
CN108864285A (zh) * 2008-01-03 2018-11-23 斯克里普斯研究院 通过模块识别结构域的抗体靶向
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
KR101238061B1 (ko) 2009-03-31 2013-02-27 한화케미칼 주식회사 Ｖｃａｍ－１에 특이적으로 결합하는 인간 단일클론항체 및 그를 포함하는 염증성 질환 또는 암의 치료용 조성물
EP2558499B1 (en) * 2010-04-16 2017-04-12 Biogen MA Inc. Anti-vla-4 antibodies
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
US20140135483A1 (en) * 2011-06-30 2014-05-15 Gene Techno Science Co., Ltd. Soluble integrin alpha-4 mutant
US10150800B2 (en) 2013-03-15 2018-12-11 Zyngenia, Inc. EGFR-binding modular recognition domains
CN103215223B (zh) * 2013-03-18 2014-10-29 中国人民解放军第四军医大学 人椎间盘髓核细胞和免疫细胞相互作用的体外模型构建方法
CN103838980A (zh) * 2014-03-27 2014-06-04 山东大学 对多发性骨髓瘤骨病治疗方法的疗效进行模拟评测的方法
CN105688185B (zh) * 2016-03-13 2019-03-19 浙江药苑生物科技有限公司 一种用于治疗骨髓增生、骨癌的药物组合物及其用途
WO2017205560A1 (en) * 2016-05-27 2017-11-30 Albert Einstein College Of Medicine, Inc. Methods for treating cancer by targeting vcam1 and maea
US11560433B2 (en) 2016-05-27 2023-01-24 Albert Einstein College Of Medicine Methods of treatment by targeting VCAM1 and MAEA

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6307025B1 (en) 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5217870A (en) 1989-04-28 1993-06-08 Biogen, Inc. Monoclonal antibodies against CDX
US5272263A (en) 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5260277A (en) 1990-09-10 1993-11-09 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
WO1992008464A1 (en) 1990-11-15 1992-05-29 Tanabe Seiyaku Co. Ltd. Substituted urea and related cell adhesion modulation compounds
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
JPH07506091A (ja) 1992-01-13 1995-07-06 バイオゲン　インコーポレイテッド 喘息の処置
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
ATE151642T1 (de) 1992-02-12 1997-05-15 Biogen Inc Behandlung für entzündungserkrankung des darmes
EP0670735B1 (en) 1992-11-13 1997-04-02 Board Of Regents Of The University Of Washington Peripheralization of hematopoietic stem cells
EP0677060A1 (en) 1993-01-08 1995-10-18 Tanabe Seiyaku Co., Ltd. Peptide inhibitors of cell adhesion
EP0678122B1 (en) 1993-01-12 1999-07-28 Biogen, Inc. Recombinant anti-vla4 antibody molecules
EP0682529B2 (en) 1993-02-09 2005-12-28 Biogen Idec MA, Inc. Antibody for the treatment of insulin dependent diabetes
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
CA2182013C (en) * 1994-01-25 2007-07-17 Mary M. Bendig Humanized antibodies against leukocyte adhesion molecule vla-4
US5510332A (en) * 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US5885786A (en) 1996-04-19 1999-03-23 John Wayne Cancer Institute Methods for screening of substances for inhibition of multidrug resistance
ATE326238T1 (de) 1996-06-27 2006-06-15 Chugai Pharmaceutical Co Ltd Mittel gegen myelome, welches zusammen mit antitumorwirkstoffen auf der basis von stickstoff-senfgasen verwendet werden kann
YU75500A (sh) * 1998-05-28 2002-12-10 Biogen Inc. NOVI VLA-4 INHIBITORI oMePUPA-V
US9501219B2 (en) 2012-01-25 2016-11-22 Oracle International Corporation 2D line data cursor
US9713013B2 (en) 2013-03-15 2017-07-18 Elwha Llc Protocols for providing wireless communications connectivity maps
US9400266B2 (en) 2013-03-14 2016-07-26 Rosemount Analytical Inc. Gas chromatograph with improved operation
US9104862B2 (en) 2013-04-01 2015-08-11 Uniquesoft, Llc Secure computing device using new software versions

Also Published As

Publication number Publication date
SK287601B6 (sk) 2011-03-04
CN1236815C (zh) 2006-01-18
EE05558B1 (et) 2012-08-15
WO2000015247A3 (en) 2000-05-25
IL141877A0 (en) 2002-03-10
HUP0103630A3 (en) 2004-03-01
EA200100362A1 (ru) 2001-12-24
CZ302997B6 (cs) 2012-02-15
DE69940206D1 (de) 2009-02-12
CN1321091A (zh) 2001-11-07
BR9913705A (pt) 2001-06-05
EE200100146A (et) 2002-06-17
CA2343579A1 (en) 2000-03-23
HU229038B1 (hu) 2013-07-29
JP5378303B2 (ja) 2013-12-25
EP1113810A2 (en) 2001-07-11
PT1113810E (pt) 2009-03-10
KR100628818B1 (ko) 2006-09-27
NO20011283D0 (no) 2001-03-14
SI1113810T1 (sl) 2009-04-30
JP2013241441A (ja) 2013-12-05
EP1113810B1 (en) 2008-12-31
JP2010235620A (ja) 2010-10-21
AU757873B2 (en) 2003-03-06
NO20011244D0 (no) 2001-03-12
CA2343579C (en) 2012-05-29
NO20011244L (no) 2001-05-14
ZA200102032B (en) 2002-11-07
PL347128A1 (en) 2002-03-25
US20020022028A1 (en) 2002-02-21
DK1113810T3 (da) 2009-04-06
IL197686A0 (en) 2011-07-31
WO2000015247A8 (en) 2009-12-23
ATE418999T1 (de) 2009-01-15
SK6052001A3 (en) 2001-12-03
ES2319831T3 (es) 2009-05-12
JP2002524529A (ja) 2002-08-06
WO2000015247A2 (en) 2000-03-23
CY1109413T1 (el) 2014-08-13
KR20010085793A (ko) 2001-09-07
TR200100734T2 (tr) 2001-07-23
NO327855B1 (no) 2009-10-05
PL203114B1 (pl) 2009-08-31
NZ511062A (en) 2003-04-29
EA004270B1 (ru) 2004-02-26
EP2065050A1 (en) 2009-06-03
CZ2001916A3 (cs) 2001-08-15
US7211252B2 (en) 2007-05-01
IS5856A (is) 2001-02-23
AU6248699A (en) 2000-04-03
IS2631B (is) 2010-06-15
HUP0103630A2 (hu) 2002-01-28

Similar Documents

Publication Publication Date Title
HK1038313A1 (en) Methods of treating multiple myeloma and myeloma-induced bone resorption using antagonists of integrin / receptor binding
ATE271393T1 (de) Zusammensetzungen zur erhöhung des hautdurchtritts von arzneistoffen unter verwendung von permeationsbeschleunigern
DE69939022D1 (de) Epidermale wachstumsfaktor rezeptor antagonisten zur behandlung stark vermehrter schleimsekretion in der lunge
DE59902314D1 (de) Oligomerisiertes Organopolysiloxan-Cokondensat, dessen Herstellung und dessen Verwendung zur Behandlung von Oberflächen
WO2003103581A3 (en) COMPOSITIONS AND METHODS FOR LIVER GROWTH AND PROTECTION
IT1303790B1 (it) "apparecchiatura impiantabile di rilevazione elettromiograficainterno-esterno, in particolare per lo studio in vivo dell'attivita'
DE69738045D1 (de) Verwendung von cetrorelix zur behandlung von benigne prostatahypertrophie und prostatakrebs
IL106894A0 (en) Dorsal tissue affecting factor and compositions
ATE258062T1 (de) Verwendung von wachstumshormon freisetzenden stoffen und ihren antagonisten zur behandlung von tumoren
WO2002092013A3 (en) Methods for treating liver disease and liver damage with growth hormone and foxm1b
EP0871457A4 (en) ISOLATED STROMA CELLS AND THEIR METHOD OF USE
MXPA02005069A (es) Agentes de enlace especificos para t3 y metodos para su uso.
IL140044A0 (en) Compounds with growth hormone releasing properties
EP2236619A3 (en) BCL2L12 polypeptide activators and inhibitors
ATE332970T1 (de) Verfahren und zusammensetzungen zur hemmung von neoplastischem zellwachstums
DE29903855U1 (de) Implantat zum Aneinanderbefestigen von Knochen
IL142579A0 (en) Compounds with growth hormone releasing properties
IL120291A0 (en) Anti proliferative compositions obtained from plant cell or tissue culture
ITTV970049A0 (it) Procedimento ed apparecchiatura per l'abbronzatura artificiale.
ZA200109347B (en) Treatment of refractory human tumors with epidermal growth factor receptor antagonists.
ZA9710452B (en) Compositions and methods for the preservation of living tissues.
GB9716957D0 (en) Cell culture substrate for evaluating the resorptive activities of bone cells

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150913